Cerebrospinal fluid tau (total and phosphorylated) and amyloid-β have been extensively studied as individual biomarkers, and their combination has improved their diagnostic performance for identifying patients with Alzheimer’s disease [35,129]. Here, MAPT is linked to Alzheimer disease.